Provides Independent, Real-World Global View of Direct-to-Device Activity BOSTON–(BUSINESS WIRE)–Opensignal, a global independent consumer connectivity analytics and insights company, today launched the Opensignal D2D Satellite Map, the world’s first interactive, real-world depiction of where direct-to-device (D2D) satellite connections with smartphones are happening across the globe. Every point on the map, which will be updated monthly, …
From a full line of Wi‑Fi 8 Products to industrial Edge AI, CIG will demonstrate technologies designed to create more value across the network VIENNA–(BUSINESS WIRE)–#EdgeAI–Cambridge Industries Group (CIG), a global leader in broadband and optical connectivity technologies, will showcase its latest broadband, optical, and Edge AI platform innovation at Network X 2026, October 13-15 …
New active ingredient Cyclopyranil effectively controls weeds resistant to common herbicides BASEL, Switzerland & TOKYO–(BUSINESS WIRE)–Syngenta, the global leader in agricultural innovation, and Kyoyu Agri Co. Ltd, a leading Japanese agrochemical manufacturer, today announced a strategic collaboration to bring high-performance herbicide solutions based on the active ingredient Cyclopyranil, which is a novel active ingredient developed …
Continue reading “Syngenta and Kyoyu Agri Partner on Innovative Rice Herbicide”
FDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a …
SAN DIEGO–(BUSINESS WIRE)–$BULL #BULL–Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of persons or entities who purchased or otherwise acquired Webull Corporation (NASDAQ: BULL) securities between April 26, 2025 and October 6, 2026, inclusive (the “Class Period”). Webull operates as a digital investment platform. The complaint alleges …
Humorous brand awareness campaign with an e.l.f. twist spotlights Save Your e.l.f. Hypochlorous Mist that helps soothe stressed skin and beyond OAKLAND, Calif.–(BUSINESS WIRE)–e.l.f. SKIN, a brand from e.l.f. Beauty (NYSE: ELF), answers community mist-mergencies in an all-new brand awareness campaign that highlights everyday stressors – and how to help soothe them. Spotlighting e.l.f. SKIN’s …
SAN DIEGO–(BUSINESS WIRE)–$DUOL #DUOL–Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons who purchased Duolingo, Inc. (NASDAQ: DUOL) Class A common stock between May 2, 2025 and February 26, 2026, inclusive (the “Class Period”). Duolingo is a leading, U.S.-based mobile learning platform that primarily focuses …
An affiliate of KKR & Co. Inc., a leading global investment firm and investor in Crescent, has agreed to purchase 40,000,000 shares as part of the offering HOUSTON–(BUSINESS WIRE)–Crescent Energy Company (“Crescent” or the “Company”) (NYSE: CRGY) today announced the pricing of an underwritten, public offering of 80,000,000 shares of its Class A common stock, …
Veteran medtech finance executive brings more than two decades of spine and M&A leadership experience NEW YORK–(BUSINESS WIRE)–VB Spine LLC (“VB Spineˮ), the largest privately held spine company, today announced the appointment of Thomas E. Oglesby as Chief Financial Officer, effective Sept. 16, 2026. Oglesby joins VB Spine from Zimmer Biomet, where he most recently …
Continue reading “VB Spine Appoints Thomas E. Oglesby as New Chief Financial Officer”
Randomized, double-blind, placebo-controlled study will evaluate two doses of FRP-003 in approximately 220 adults with Long COVID and persistent fatigue DENVER–(BUSINESS WIRE)–#COVID–Front Range Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for FRP-003, allowing the company to proceed with a Phase 2 clinical …